• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Scholar Rock Holding Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

    6/3/25 4:02:04 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRRK alert in real time by email
    0001727196false00017271962025-06-032025-06-03

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    ​

    FORM 8-K

    ​

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event Reported): June 3, 2025

    ​

    Scholar Rock Holding Corporation

    (Exact Name of Registrant as Specified in Charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Delaware

        

    001-38501

        

    82-3750435

    (State or Other Jurisdiction of
    Incorporation)

    ​

    (Commission File Number)

    ​

    (I.R.S. Employer Identification Number)

    ​

    301 Binney Street, 3rd Floor, Cambridge, MA 02142

    (Address of Principal Executive Offices) (Zip Code)

    ​

    (857) 259-3860

    (Registrant’s telephone number, including area code)

    ​

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ​

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ​

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ​

    ​

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ​

    ​

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

    SRRK

    The Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    Item 4.01. Changes in Registrant’s Certifying Accountant.

     

    (b) Engagement of New Independent Registered Public Accounting Firm

     

    On June 3, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of Scholar Rock Holding Corporation (the “Company”) appointed Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The Audit Committee conducted a competitive process in which multiple firms were invited to participate to select a firm to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

    During the fiscal years ended December 31, 2024 and 2023 and the subsequent interim period through June 3, 2025, neither the Company nor anyone on its behalf consulted with Deloitte with respect to (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, and neither a written report nor oral advice was provided to the Company that Deloitte concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (b) any matter that was either the subject of a “disagreement” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto) or a “reportable event” (as described in Item 304(a)(1)(v) of Regulation S-K).

    ​

    ​

    ​

    ​

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Scholar Rock Holding Corporation

     

     

     

    Date: June 3, 2025

    By:

    /s/ Junlin Ho

     

     

    Junlin Ho

     

     

    General Counsel & Corporate Secretary

    ​

    ​

    ​

    Get the next $SRRK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SRRK

    DatePrice TargetRatingAnalyst
    11/26/2024$40.00 → $50.00Buy
    H.C. Wainwright
    10/7/2024$30.00 → $35.00Buy
    H.C. Wainwright
    3/28/2024$30.00Strong Buy
    Raymond James
    10/25/2023$20.00Hold → Buy
    Jefferies
    4/3/2023$26.00Overweight
    Piper Sandler
    9/19/2022$30.00Buy
    H.C. Wainwright
    7/12/2022$20.00Buy
    Truist
    3/23/2022$24.00Buy
    H.C. Wainwright
    More analyst ratings

    $SRRK
    SEC Filings

    See more
    • Scholar Rock Holding Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Scholar Rock Holding Corp (0001727196) (Filer)

      6/18/25 7:10:13 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Scholar Rock Holding Corporation

      144 - Scholar Rock Holding Corp (0001727196) (Subject)

      6/5/25 4:57:15 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Holding Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant

      8-K - Scholar Rock Holding Corp (0001727196) (Filer)

      6/3/25 4:02:04 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Flier Jeffrey S. exercised 20,316 shares at a strike of $21.62 and sold $1,024,722 worth of shares (31,452 units at $32.58) (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      6/25/25 4:30:05 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF SCIENTIFIC OFFICER Qatanani Mo sold $117,381 worth of shares (3,668 units at $32.00), decreasing direct ownership by 3% to 139,561 units (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      6/17/25 4:30:18 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Peng Katie sold $96,888 worth of shares (3,031 units at $31.97), decreasing direct ownership by 8% to 34,920 units (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      6/17/25 4:30:19 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright reiterated coverage on Scholar Rock with a new price target

      H.C. Wainwright reiterated coverage of Scholar Rock with a rating of Buy and set a new price target of $50.00 from $40.00 previously

      11/26/24 8:04:27 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright reiterated coverage on Scholar Rock with a new price target

      H.C. Wainwright reiterated coverage of Scholar Rock with a rating of Buy and set a new price target of $35.00 from $30.00 previously

      10/7/24 9:45:10 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Scholar Rock with a new price target

      Raymond James initiated coverage of Scholar Rock with a rating of Strong Buy and set a new price target of $30.00

      3/28/24 7:48:04 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

      Oral presentation on the positive Phase 3 SAPPHIRE trial of apitegromab for people living with spinal muscular atrophy (SMA), which demonstrated statistically significant improvement and clinically meaningful benefit as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE) Apitegromab Biologics License Application (BLA) accepted under priority review for patients with SMA, and U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) date set for September 22 European Medicines Agency (EMA) validated Marketing Authorisation Application (MAA) for apitegromab for patients with SMA Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company f

      6/23/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

      Patients receiving apitegromab with tirzepatide over 24 weeks showed a 54.9% preservation of lean mass (+4.2 lbs of lean mass) versus tirzepatide alone (p=0.001) Patients receiving apitegromab with tirzepatide over 24 weeks lost 18.8 lbs of fat mass while those on tirzepatide alone lost 17.7 lbs of fat mass Patients receiving apitegromab with tirzepatide over 24 weeks lost 12.3% of body weight while those on tirzepatide alone lost 13.4% of body weight Higher quality of weight loss observed for patients receiving apitegromab with tirzepatide (85% fat mass/15% lean mass) compared to tirzepatide alone (70% fat mass/30% lean mass) Apitegromab was generally well tolerated, and t

      6/18/25 7:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 309,700 shares of its common stock to 11 newly hired employees, consisting of inducement stock options to purchase an aggregate of 176,963 shares of common stock and inducement restricted stock units, covering an aggregate of 132,737 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 20

      6/13/25 4:15:00 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Akkaraju Srinivas bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      10/18/23 5:46:02 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Samsara Biocapital Gp, Llc bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      10/18/23 5:44:33 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invus Public Equities, L.P. bought $15,086,736 worth of shares (2,199,931 units at $6.86) (SEC Form 4)

      4 - Scholar Rock Holding Corp (0001727196) (Issuer)

      10/16/23 5:46:56 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Leadership Updates

    Live Leadership Updates

    See more
    • Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

      - Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co

      8/16/21 4:05:00 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Financials

    Live finance-specific insights

    See more
    • Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

      Oral presentation on the positive Phase 3 SAPPHIRE trial of apitegromab for people living with spinal muscular atrophy (SMA), which demonstrated statistically significant improvement and clinically meaningful benefit as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE) Apitegromab Biologics License Application (BLA) accepted under priority review for patients with SMA, and U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) date set for September 22 European Medicines Agency (EMA) validated Marketing Authorisation Application (MAA) for apitegromab for patients with SMA Scholar Rock (NASDAQ:SRRK), a late-stage biopharmaceutical company f

      6/23/25 8:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

      Patients receiving apitegromab with tirzepatide over 24 weeks showed a 54.9% preservation of lean mass (+4.2 lbs of lean mass) versus tirzepatide alone (p=0.001) Patients receiving apitegromab with tirzepatide over 24 weeks lost 18.8 lbs of fat mass while those on tirzepatide alone lost 17.7 lbs of fat mass Patients receiving apitegromab with tirzepatide over 24 weeks lost 12.3% of body weight while those on tirzepatide alone lost 13.4% of body weight Higher quality of weight loss observed for patients receiving apitegromab with tirzepatide (85% fat mass/15% lean mass) compared to tirzepatide alone (70% fat mass/30% lean mass) Apitegromab was generally well tolerated, and t

      6/18/25 7:00:00 AM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 309,700 shares of its common stock to 11 newly hired employees, consisting of inducement stock options to purchase an aggregate of 176,963 shares of common stock and inducement restricted stock units, covering an aggregate of 132,737 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 20

      6/13/25 4:15:00 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

      SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

      11/14/24 9:00:58 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

      SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

      11/14/24 7:24:55 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

      SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

      11/14/24 1:22:38 PM ET
      $SRRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care